Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: A Review of Recent Clinical Trials

Author(s): Carrie B. Lee, Mark A. Socinski

Journal Name: Reviews on Recent Clinical Trials

Volume 2 , Issue 2 , 2007

Become EABM
Become Reviewer
Call for Editor


Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality in the United States. Therapeutic agents that target the underlying biology of this disease are necessary to improve outcomes. Angiogenesis plays a central role in NSCLC tumor growth and metastases. The vascular endothelial growth factor pathway (VEGF) as a therapeutic target was recently validated in NSCLC. Since then, a multitude of early phase clinical trials that incorporate the use of angiogenesis inhibitors, either as single agents or in combination with cytotoxic chemotherapy, have been conducted in advanced, refractory NSCLC. This article reviews these clinical trials with attention to toxicity, efficacy, and direction of further study. The data from these trials suggest that optimal use of antiangiogenic agents in NSCLC is more likely in combination with standard cytotoxic agents, however the most effective combination with the least toxicity is yet to be determined.

Keywords: Sunitinib, Vatalanib, Sorafenib, AMG 706, AZD2171

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Published on: 01 March, 2012
Page: [117 - 120]
Pages: 4
DOI: 10.2174/157488707780599401
Price: $65

Article Metrics

PDF: 6